An area of the brain where tumor cells shelter from chemotherapy in childhood leukaemia
(Universidad Complutense de Madrid) Sometimes, the central nervous system harbours tumour cells that elude treatment and thus become one of the main sources of relapse. Research led by the Complutense University of Madrid has identified one of these locations in which the cells remain protected: the stroma of the choroid plexus, a structure in the brain ventricles responsible for the production of cerebrospinal fluid. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 25, 2020 Category: International Medicine & Public Health Source Type: news

New NCCN resource for understanding childhood leukemia
(National Comprehensive Cancer Network) NCCN publishes a new patient and caregiver resource focused on a childhood cancer type. Free NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia (ALL) shares the latest expert advice for treating infants, children, and adolescents with the most common pediatric malignancy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 23, 2020 Category: Cancer & Oncology Source Type: news

Penn researchers discover potential cause of immunotherapy-related neurotoxicity
(University of Pennsylvania School of Medicine) New research has uncovered the previously unknown presence of CD19 -- a B cell molecule targeted by chimeric antigen receptor (CAR) T cell immunotherapy to treat leukemia, lymphoma, and multiple myeloma -- in brain cells that protect the blood brain barrier (BBB). This discovery may potentially be the cause for neurotoxicity in patients undergoing CD19 directed CAR T cell immunotherapy, according to the research team led by Avery Posey, PhD, an assistant professor of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 21, 2020 Category: Cancer & Oncology Source Type: news

New way to halt leukemia relapse shown promising in mice
(Hiroshima University) Drugs tackling chronic myelogenous leukemia have completely transformed prognoses of patients over the last couple of decades, with most cases going into remission. But drug resistance can occur, leading to relapses. Targeting the lipids involved in regulating part of a leukemia stem cell's life span offers a potential second route to defeat the disease--and solid tumorous cancers as well. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 18, 2020 Category: Biology Source Type: news

The Josep Carreras Institute identifies a marker of poor evolution in Hodgkin's lymphoma
(Josep Carreras Leukaemia Research Institute) Dr. Manel Esteller, director of the Josep Carreras Leukemia Research Institute, published today in Blood journal, the discovery of a marker that allows predicting which patient with Hodgkin's lymphoma will present the aggressive clinical course, and will therefore be a case of special risk. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 15, 2020 Category: Cancer & Oncology Source Type: news

Inherited genetic variant influences response to leukemia treatment for some children
(St. Jude Children's Research Hospital) St. Jude researchers showed that an inherited variant of the GATA3 gene is tied to minimal residual disease levels and response to therapy for acute lymphoblastic leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2020 Category: Cancer & Oncology Source Type: news

Which Drug Therapy for CLL, Time-Limited or Continuous? Which Drug Therapy for CLL, Time-Limited or Continuous?
With several different options now available for drug treatment of chronic lymphocytic leukemia (CLL), discussions have become lengthy as the choice needs to be individualized, one expert says.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 9, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Leukemia: Signs, Symptoms, And Complications
Title: Leukemia: Signs, Symptoms, And ComplicationsCategory: Diseases and ConditionsCreated: 9/9/2020 12:00:00 AMLast Editorial Review: 9/9/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 9, 2020 Category: Cancer & Oncology Source Type: news

Feline leukaemia virus infection: A clinical and epidemiological enigma
(SAGE) Feline leukaemia virus (FeLV) is a gammaretrovirus that occurs worldwide in domestic cats, as well as small wild cats. It is associated with various serious, and sometimes fatal, diseases including anaemia, immunosuppression and certain cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 9, 2020 Category: Cancer & Oncology Source Type: news

How Does Leukemia Affect the Body?
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 8, 2020 Category: General Medicine Source Type: news

MD Anderson and Astex Pharmaceuticals announce strategic collaboration to accelerate clinical evaluation of therapies for patients with leukemia
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex's pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). The collaboration will combine MD Anderson's clinical trials infrastructure and expertise with Astex's clinical pipeline p...
Source: EurekAlert! - Cancer - September 8, 2020 Category: Cancer & Oncology Source Type: news

New insights into why people with down syndrome are at higher risk for leukemia
(Ann& Robert H. Lurie Children's Hospital of Chicago) Scientists from Stanley Manne Children's Research Institute at Ann& Robert H. Lurie Children's Hospital of Chicago were the first to examine endothelial cells - one of the main sources of blood production - for clues as to why people with Down syndrome have higher prevalence of leukemia. They identified a new set of genes that are overexpressed in endothelial cells of patients with Down syndrome. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 8, 2020 Category: Cancer & Oncology Source Type: news

Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia
SUZHOU, China and ROCKVILLE, Md., Sept. 7, 2020 -- (Healthcare Sales & Marketing Network) -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),... Biopharmaceuticals, Oncology, FDA Ascentage Pharma, APG-2575, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves First Maintenance Therapy for AML FDA Approves First Maintenance Therapy for AML
The FDA has approved an oral formulation of azacitidine for the continued treatment of adults with acute myeloid leukemia (AML) who have achieved initial complete remission.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Making another run at cancer, S.F. biotech corrects course after clinical trial failure
Even as an early-stage study failed with one drug in 2018, Cleave Therapeutics Inc. were readying a next-generation drug against acute myeloid leukemia. It enrolled the first patient this summer in the new drug's first clinical trial. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 2, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Making another run at cancer, S.F. biotech corrects course after clinical trial failure
Even as an early-stage study failed with one drug in 2018, Cleave Therapeutics Inc. were readying a next-generation drug against acute myeloid leukemia. It enrolled the first patient this summer in the new drug's first clinical trial. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 2, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

FDA Approves Onureg (azacitidine tablets) as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
PRINCETON, N.J.--(BUSINESS WIRE) September 1, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Onureg (azacitidine 300 mg tablets, CC-486) for the continued treatment of adult... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 2, 2020 Category: Drugs & Pharmacology Source Type: news

FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia
FDA approved azacitidine tablets (ONUREG ®, Celgene Corporation) for acute myeloid leukemia. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 1, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

INQOVI (decitabine and cedazuridine) Tablets, FDA Approved for Treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, Available at Biologics by McKesson
CARY, N.C., Aug. 24, 2020 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Taiho Oncology, Inc. as a specialty pharmacy provider for INQOVI® (decitabine and cedazuridine) tablets for the treatment of adults with intermedia... (Source: McKesson News)
Source: McKesson News - August 24, 2020 Category: Information Technology Source Type: news

Late Morbidity, Mortality Down for Survivors of Childhood ALL
THURSDAY, Aug. 20, 2020 -- Contemporary survivors of childhood acute lymphoblastic leukemia (ALL) have reduced late morbidity and mortality, according to a study published online July 24 in the Journal of Clinical Oncology. Stephanie B. Dixon,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 21, 2020 Category: Pharmaceuticals Source Type: news

Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment
Guidance for Industry: Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 17, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Drug Combo Prolongs Survival in Acute Myeloid Leukemia
Findings seen for azacitidine + venetoclax in older patients ineligible for intensive chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 13, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

Drug Combo Prolongs Survival in Acute Myeloid Leukemia
THURSDAY, Aug. 13, 2020 -- Overall survival is longer and the incidence of remission is higher among previously untreated, older patients with acute myeloid leukemia (AML) who receive azacitidine plus venetoclax versus azacitidine alone, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 13, 2020 Category: Pharmaceuticals Source Type: news

Doctors order thyroid ultrasounds without good reasons
About one-third of physicians have ordered thyroid ultrasound scans for patients...Read more on AuntMinnie.comRelated Reading: Is thyroid cancer overdiagnosed for 9/11 first responders? Does thyroid cancer screening lead to overdiagnosis? CT radiation increases risk of thyroid cancer, leukemia AI boosts ultrasound for thyroid cancer screening New thyroid test could help patients avoid surgery (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 13, 2020 Category: Radiology Source Type: news

NUS research breakthrough: CircASXL1-1 regulates BAP1 deubiquitinase activity in leukemia
(National University of Singapore) Researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) have identified covalently closed circular RNAs (circRNAs) from key genes involved in leukemia development and provided greater understanding of their roles in haematological malignancies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 13, 2020 Category: Cancer & Oncology Source Type: news

Azacitidine + Venetoclax Combo Benefits Older Patients With AML Azacitidine + Venetoclax Combo Benefits Older Patients With AML
The treatment regimen improved overall survival and remission rates with rapid responses in the tough-to-treat population of older patients with acute myeloid leukemia (AML).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 12, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Ball Score Predicts Benefit From Ibrutinib in CLL Ball Score Predicts Benefit From Ibrutinib in CLL
The BALL score was able to identify a subset of patients with chronic lymphocytic leukemia (CLL) who particularly benefited from single-agent ibrutinib therapy, according to a study of 111 patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 12, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASH Issues Guidelines on Newly Diagnosed AML in Older Adults
WEDNESDAY, Aug. 12, 2020 -- In evidence-based guidelines issued by the American Society of Hematology and published in the Aug. 11 issue of Blood Advances, recommendations are presented for the management of newly diagnosed acute myeloid leukemia... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 12, 2020 Category: Pharmaceuticals Source Type: news

Combination therapy improves survival outcomes for patients with acute myeloid leukemia
(University of Texas M. D. Anderson Cancer Center) A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 12, 2020 Category: International Medicine & Public Health Source Type: news

A cancer mystery of more than 40 years ago is solved thanks to epigenetics
(Josep Carreras Leukaemia Research Institute) In an article that was just published in Proceedings of the National Academy of Sciences (PNAS) by the group of Dr. Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute, ICREA Research Professor and Professor of Genetics at the University of Barcelona is solved this mystery by describing that in cancer cells the protein that generates the nucleotide " Y " is epigenetically inactivated, causing small but highly aggressive tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 12, 2020 Category: Cancer & Oncology Source Type: news

Understanding 'Chemo Brain' in Children: Researchers Secure $4.6 Million NIH Grant to Identify Those at Risk
August 11, 2020—(BRONX, NY)—Chemotherapy usually cures children diagnosed with acute lymphoblastic leukemia (ALL), but the treatment may hamper brain development and impact key cognitive functions including sensory processing, memory, and attention. Researchers atAlbert Einstein College of Medicine,Children’s Hospital at Montefiore (CHAM), andRutgers Cancer Institute of New Jersey have received a five-year, $4.6 million grant from the National Institutes of Health (NIH) to determine how chemotherapy exerts its damaging effects on the brain. Their long-term objective is to use this information to develop p...
Source: Einstein News - August 11, 2020 Category: Universities & Medical Training Source Type: news

New study may refine predicted survival outcomes and treatment in younger adults with acute leukemia
(Ohio State University Wexner Medical Center) The findings of a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute could refine an important set of prognostic and treatment recommendations for younger adult patients with acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 5, 2020 Category: Cancer & Oncology Source Type: news

Mesothelioma T-Cell Therapy Shows Early Effectiveness in Trial
A mesothelioma clinical trial involving genetically modified T cells has opened to considerable acclaim, shrinking tumors in the first five patients who were treated. The phase I portion of the clinical trial is designed to define the safety profile and optimal dosage level of TC-210, a novel immunotherapy targeting mesothelin, a cell-surface protein often overexpressed in several cancers. While T cell modifications in the laboratory are proving safe and well tolerated, the initial signs of consistent efficacy became an early bonus in phase I. Four of the patients treated had mesothelioma. The fifth had ovarian cancer. All...
Source: Asbestos and Mesothelioma News - August 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Identified gene mutations impact on the severity of a type of hematologic cancer
(Josep Carreras Leukaemia Research Institute) Researchers from Josep Carreras Leukemia Research Institute participate in an international study that confirms for the first time that mutation of the two TP53 gene's copies is associated with a worse prognosis in myelodysplastic syndromes, a group of blood cancers a more frequent in elderly population. The results of this study have been published in Nature Medicine journal and represent an advance in the diagnosis and treatment of this type of hematological cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 4, 2020 Category: Cancer & Oncology Source Type: news

Cladribine With Concurrent or Delayed Rituximab in HCL Cladribine With Concurrent or Delayed Rituximab in HCL
Could the addition of rituximab to cladribine treatment help clear minimal residual disease in patients with hairy cell leukemia?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 3, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Large international study pinpoints impact of TP53 gene mutations on blood cancer severity
(Memorial Sloan Kettering Cancer Center) A large international study led by researchers at Memorial Sloan Kettering has immediate clinical relevance for risk assessment and treatment of people with myelodysplastic syndrome and acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 3, 2020 Category: Cancer & Oncology Source Type: news

UArizona Health Sciences researcher seeks safer, more effective leukemia treatment
(University of Arizona Health Sciences) A potentially safer, more effective chemotherapy treatment for patients with blood-related cancers, such as leukemia, who need a particular bone marrow transplant procedure is under study at the University of Arizona Health Sciences. The procedure is known as a haploidentical (half-matched) bone marrow transplantation, or " haplo-BMT, " providng an alternate source of stem cells for patients needing a bone marrow transplant but unable to find a perfect or near-perfect donor match for human leukocyte antigens. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 3, 2020 Category: Cancer & Oncology Source Type: news

Survivors of Adolescent, Young Adult ALL May Suffer Late Effects
FRIDAY, July 31, 2020 -- Survivors of adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) may experience late effects, with a high incidence of subsequent endocrine disease and cardiac disease, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2020 Category: Pharmaceuticals Source Type: news

Huntsman Cancer Institute illuminates potential new treatment in acute myeloid leukemia
(Huntsman Cancer Institute) In a study published in the journal Leukemia, lead author Ami Patel, MD, Huntsman Cancer Institute researcher and assistant professor in the Division of Hematology and Hematologic Malignancies at the University of Utah, showed that factors produced by bone marrow support cells allowed leukemia cells to survive treatment with quizartinib, a type of TKI. When quizartinib was combined with another TKI called dasatinib the alternative survival pathways were shut down, leading to more effective leukemia cell death. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 31, 2020 Category: Cancer & Oncology Source Type: news

Cell competition in the thymus is crucial in a healthy organism
(Instituto Gulbenkian de Ciencia) The study published in Cell Reports demonstrates that the development of T lymphocytes lays on the coordination of signals followed by cells in order to ensure the maintenance of a healthy organism. The cells identified in the study integrate information regarding the needs of more mature cells and define their own development accordingly: adjusting the speed of the production of T lymphocytes and purging the system of other less efficient cells, that tend to cause leukemia. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 30, 2020 Category: Biology Source Type: news

Cancer, Religion and a ‘Good’ Death
It is hard to know how much my patient, caught in an eternal childhood, understood about his cancer. (Source: NYT Health)
Source: NYT Health - July 28, 2020 Category: Consumer Health News Authors: Mikkael A. Sekeres, M.D. Tags: Leukemia Hospitals Coma Cancer Doctors Religion and Belief Death and Dying Source Type: news

Identified a new regulatory mechanism of response to metabolic stress
(Josep Carreras Leukaemia Research Institute) The Chromatin Biology group, led by Dr. Alex Vaquero has identified a new enzymatic activity in SIRT7, involved in stress response, aging and hematopoiesis, which plays a key role in metabolic stress and aging. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 27, 2020 Category: Biology Source Type: news

2 immunotherapies merged into single, more effective treatment
(Washington University School of Medicine) Researchers at Washington University School of Medicine in St. Louis have combined two immunotherapy strategies into a single therapy and found, in studies in human cells and in mice, that the two together are more effective than either alone in treating certain blood cancers, such as leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2020 Category: Cancer & Oncology Source Type: news

Patient centricity: Mind the capacity gap
Pharmaceutical companies and regulators are in need of increasing amounts of input from patients throughout the entire product development lifecycle, from identifying what questions to ask in the earliest stages of research through clinical development to approval.    This usually means partnering with patient organisations and advocacy groups but pharma ’s ambitions here frequently come up against a problem. Very often, both industry and patient organisations are not set up to participate in these processes – with industry lacking systematic processes and patient advocates the required training and ...
Source: EyeForPharma - July 21, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Stalled Gilead leukemia drug ignites former top scientist ’s new company
Norbert Bischofberger liked what he saw from a Gilead cancer drug at the time, but it just wasn't effective enough at the time. Now as CEO of a biotech startup, he has more information — and he has the drug. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 21, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Leukemia drug shows the potential to treat aggressive pediatric brain c â ncer
(Funda ç ã o de Amparo à Pesquisa do Estado de S ã o Paulo) When tested in vitro, arsenic trioxide killed tumor cells and prevented the formation of new colonies. This leukemia drug also boosted the effect of radiation therapy on medulloblastoma, a type of central nervous system tumor most common in children. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 21, 2020 Category: International Medicine & Public Health Source Type: news

Lymphoma Survivors at Risk for Developing Chronic Kidney Disease
MONDAY, July 20, 2020 -- Lymphoma survivors are at substantial long-term risk for chronic kidney disease (CKD) development, according to a study published online July 11 in Leukemia& Lymphoma. Sanjal H. Desai, M.D., from the Medstar Washington... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2020 Category: Pharmaceuticals Source Type: news

A spin-off to develop therapies for leukaemia based on CAR-T, by Josep Carreras Institute
(Josep Carreras Leukaemia Research Institute) Invivo Ventures, CDTI-Innvierte (Spanish Ministry of Industry) and the Josep Carreras Foundation have established a first round of funding of € 3,050,000. OCI will carry out three projects, the most advanced of which is a CAR-T CD1a (OCI-1) project for the treatment of cortical T-cell acute lymphoblastic leukemia (coT-ALL), a subtype of leukaemia that mainly affects children and which has a poor prognosis if patients do not respond to standard treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2020 Category: International Medicine & Public Health Source Type: news

What Are Some Pediatric Oncological Emergencies?
Discussion Pediatric cancers in the US number about 12,000 per year. After injury, it is the second leading cause of death in children and adolescents. Cancer presentations vary widely, but often begin with non-specific symptoms that continue or progress depending on the location and tumor type. Patients can present with oncological emergencies especially if there are mechanical obstruction such as superior vena cava syndrome or cerebral herniation. More commonly are infections due to immunosuppression. Cancer treatment also causes its own myriad of problems that clinicians need to be aware of to diagnosis and treat, but a...
Source: PediatricEducation.org - July 20, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news